Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2025 and 2026.
-
Tight liquidity NBB
Cash and receivables cover 33 % of short-term debt in 2026; threshold 65 %.
Financials
Financial year 2026
KANEKA EUROGENTEC from Seraing, company number BE0427348346, closed financial year 2026 with a result of € -20.4 million after tax. For that financial year KANEKA EUROGENTEC recorded revenue of € 49.4 million and equity of € -4,334. Compared with financial year 2025, the result moved from € -36.3 million to € -20.4 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 17, 2026.
€ -4,334
▼ € 20.8 million vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -20.4 million
▲ 44 % less loss than in 2025
Profit after tax over the fiscal year.
€ 628,642
▼ 23% vs 2025
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -35 million.
People and assets in 2026
379.2
▼ 26 vs 2025
Average over the fiscal year, from the social balance sheet.
€ 30.5 million
▼ 5% vs 2025
€ 80,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 727,174
▼ 6% vs 2025
Book value of vehicles, furniture and equipment.
Debts at end 2026
€ 65.1 million
▲ 43% vs 2025
Loans from banks and other lenders, long and short.
€ 14.6 million
▼ 17% vs 2025
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 147 days on average.
€ 5.2 million
▼ 12% vs 2025
Taxes, VAT and social contributions still to pay.
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Revenue | € 98,397,890 | € 90,196,827 | € 67,579,589 | € 49,421,165 | ▼ 27% |
| Profit after taxes | € 13,812,739 | € -5,104,142 | € -36,293,704 | € -20,394,259 | ▲ € 15.9 million |
| Equity | € 67,909,332 | € 57,548,886 | € 20,761,104 | € -4,334 | ▼ € 20.8 million |
| Total debts | € 84,295,967 | € 97,846,025 | € 105,274,048 | € 115,308,408 | ▲ 10% |
| Cash | € 876,356 | € 732,243 | € 816,523 | € 628,642 | ▼ 23% |
| Land & buildings | € 40,702,842 | € 40,992,146 | € 48,086,678 | € 45,953,431 | ▼ 4% |
| Retained profit | € 32,287,427 | € 21,717,903 | € -14,575,801 | € -34,970,060 | ▼ € 20.4 million |
| Dividend | € 6,831,726 | € 5,465,381 | € 0 | € 0 | |
| Bank debt | € 8,091,952 | € 45,601,804 | € 45,599,152 | € 65,088,396 | ▲ 43% |
| Balance sheet total | € 152,306,030 | € 155,496,248 | € 126,125,569 | € 115,383,572 | ▼ 9% |
| Employees (FTE) | 394.7 | 418.9 | 405.2 | 379.2 | ▼ 26 |
Key figures of KANEKA EUROGENTEC, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
What happened to KANEKA EUROGENTEC?
What happened at KANEKA EUROGENTEC in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Masaaki KIMURA stepped down as director. NBB
- Mitsuaki KITANO stepped down as director. NBB
- Masanobu SUGAWARA stepped down as director. NBB
- Kan OKABE stepped down as director. NBB
- Lieven JANSSENS stepped down as director. NBB
- New annual accounts for financial year 2026: loss of € 20.4 million. Source: NBB ↗
- Masaaki KIMURA became a director. NBB
- Mitsuaki KITANO became a director. NBB
In short
From € 13.8 million profit in 2023 to € 20.4 million loss in 2026.
Paid € 4.3 million in corporate taxes since 2023.
Best year ever: 2023, with € 13.8 million profit.
Paid out € 12.3 million in dividends to the owners in total.
Management
The stake of Kaneka Europe Holding Company comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
KANEKA EUROGENTECThe shares are held by Kaneka Europe Holding Company (100%). It owns 100% of EUROGENTEC PROTEOMICS GMBH, 100% of EUROGENTEC NORTH AMERICA, 100% of EUROGENTEC LTD, 100% of EUROGENTEC NEDERLAND, 100% of EUROGENTEC FRANCE and 25% of THYMOLUX itself.
Directors
According to the 2026 annual accounts
Masanobu SUGAWARA
Director
since 2022 · until 2028
Kan OKABE
Director
since 2022 · until 2028
Lieven JANSSENS
Managing director
since 2022 · until 2028
Masaaki KIMURA
Director
since 2024 · until 2030
Mitsuaki KITANO
Director
since 2024 · until 2030
Shareholders
Participations
EUROGENTEC PROTEOMICS GMBH
100%
EUROGENTEC NORTH AMERICA
100%
EUROGENTEC LTD
100%
EUROGENTEC NEDERLAND
100%
EUROGENTEC FRANCE
100%
25%
SYNTEZZA BIOSCIENCE LIMITED
11.2%
Establishments
Establishment units
Physical locations of this company
Rue du Bois St-Jean 5
4102 Seraing
Rue du Bois St-Jean 14
4102 Seraing
Active since 1 October 1985
Rue du Bois St-Jean 23
4102 Seraing
Active since 1 July 2021
Rue dèl Rodje Cinse 98
4102 Seraing
Active since 30 October 2023
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
OVH, FR
Domain
Domain
eurogentec.com
Registered
1999-01-05
Registrar
Network Solutions, LLC
Expires
2027-01-05
Website info
Features
Security
Details
- Company number
- 0427.348.346
- VAT number
- BE 0427.348.346
- Registered office
- Rue du Bois St-Jean 5, 4102 Seraing
- Names & denominations
- KANEKA EUROGENTEC
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 18 May 1985
- Peppol
- Active · Active since 11 Dec 2025
- Contact
- eurogentec.com
- Activities · NACE
Vervaardiging van overige farmaceutische producten
Vervaardiging van overige farmaceutische preparaten
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Vervaardiging van andere chemische producten, neg
Vervaardiging van farmaceutische grondstoffen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied